The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Long-standing patent and antitrust litigation between two rivals over the launch of generic enoxaparin (Sanofi's Lovenox) has been settled, with Amphastar Pharmaceuticals Inc. poised to receive $59.9m from Momenta Pharmaceuticals Inc. and Sandoz International GMBH, the companies announced on 19 June.
The cash will represent a significant boost to the cash holdings of Amphastar, a small generic drug maker that generated...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
